Galapagos NV (NASDAQ:GLPG) Given Consensus Recommendation of “Hold” by Brokerages

Galapagos NV (NASDAQ:GLPG) has earned an average rating of “Hold” from the five brokerages that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $36.00.

Several analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Galapagos in a research note on Thursday, January 22nd. Leerink Partners upgraded Galapagos from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 22nd. Royal Bank Of Canada lifted their price objective on Galapagos from $28.00 to $32.00 and gave the company a “sector perform” rating in a research report on Friday, November 7th. Wall Street Zen upgraded Galapagos from a “sell” rating to a “hold” rating in a research report on Tuesday, December 30th. Finally, Sanford C. Bernstein assumed coverage on Galapagos in a research note on Wednesday, November 26th. They issued a “hold” rating on the stock.

Hedge Funds Weigh In On Galapagos

Several institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in Galapagos in the second quarter valued at $1,114,000. EcoR1 Capital LLC increased its stake in Galapagos by 569.0% during the second quarter. EcoR1 Capital LLC now owns 1,036,945 shares of the biotechnology company’s stock worth $29,024,000 after acquiring an additional 881,939 shares during the last quarter. Matauro LLC purchased a new position in shares of Galapagos in the 3rd quarter worth about $1,647,000. Norges Bank purchased a new position in shares of Galapagos in the 2nd quarter worth about $3,359,000. Finally, Geode Capital Management LLC acquired a new position in shares of Galapagos in the 2nd quarter valued at about $220,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

Galapagos Stock Up 1.5%

Galapagos stock opened at $33.92 on Tuesday. Galapagos has a 12-month low of $22.59 and a 12-month high of $37.78. The firm’s 50-day moving average is $33.21 and its two-hundred day moving average is $32.69.

Galapagos Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.